胸腺肽对住院精神分裂症患者炎症指标及院内感染率的影响

Effect of thymosin on inflammatory indicators and nosocomial infection rate in inpatients with schizophrenia

目的探究胸腺肽对住院精神分裂症患者免疫炎症指标及院内感染率的影响。方法以100例精神分裂症患者作为研究对象,用随机数字表法分为对照组和观察组,每组50例。对照组给予常规抗精神病药物治疗,观察组在对照组治疗的基础上口服胸腺肽肠溶片,2组均连续治疗1个月。比较2组的免疫炎症指标、院内感染率以及精神分裂症患者生活质量量表(schizophrenia quality of life scale,SQLS)评分,统计2组不良反应的发生情况。结果治疗后,2组患者的CD3^(+)、CD4^(+)、CD8^(+)均升高,且观察组均高于对照组(P<0.05),2组的CD4^(+)/CD8^(+)比较差异无统计学意义(P>0.05);2组血清白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)及碱性成纤维细胞生长因子(basic fibroblast growth factor,b-FGF)水平均下降,且观察组均低于对照组(P<0.05);观察组的医院感染率(2.00%)显著低于对照组(14.00%),P<0.05;治疗后,2组的SQLS各维度评分及总分均降低,且观察组均低于对照组(P<0.05);2组的不良反应总发生率比较差异无统计学意义(P>0.05)。结论住院精神分裂症患者应用胸腺肽治疗,可有效改善免疫炎症指标,降低医院感染率,提高患者的生活质量。

Objective To investigate the effect of thymosin on immunoinflammatory indicators and nosocomial infection rate in inpatients with schizophrenia.Methods Using the random number table method,100 patients with schizophrenia were assigned to a control group and an observation group,with 50 cases in each group.The control group was treated with conventional antipsychotic drugs,while the observation group was treated with Thymosin Enteric-coated Tablets on the basis of control group.Both groups underwent 1 month of treatment.The immunoinflammatory indicators,nosocomial infection rate and the schizophrenia quality of life scale(SQLS)score were compared between the 2 groups.The incidence of adverse reactions was statistically analyzed.Results After treatment,the CD3^(+),CD4^(+)and CD8^(+)in the 2 groups increased,and these indicators in observation group were higher than those in the control group(P<0.05).There was no statistically significant difference in CD4^(+)/CD8^(+)between the 2 groups(P>0.05).The serum interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and basic fibroblast growth factor(b-FGF)levels in the 2 groups decreased,and the levels in the observation group were lower than those in the control group(P<0.05).The nosocomial infection rate in the observation group(2.00%)was significantly lower than that in the control group(14.00%),P<0.05.After treatment,the SQLS scores in different dimensions and the total scores of the 2 groups decreased,and the observation group had lower scores than the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Thymosin treatment can effectively improve immunoinflammatory indicators,reduce nosocomial infection rate and improve the quality of life of inpatients with schizophrenia.